(Q38141971)

29 August 2017

title

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice (English)

1 reference

29 August 2017

main subject

personalized medicine

1 reference

1 reference

10

Harold J Burstein

1 reference

29 August 2017

9

Ann H Partridge

1 reference

29 August 2017

8

Eric P Winer

1 reference

29 August 2017

7

Sara M Tolaney

1 reference

29 August 2017

1

Kathryn J Ruddy

1 reference

29 August 2017

Stephen D Desantis

2

1 reference

29 August 2017

Rebecca S Gelman

3

1 reference

29 August 2017

Alan H B Wu

4

1 reference

29 August 2017

Rinaa S Punglia

5

1 reference

29 August 2017

Erica L Mayer

6

1 reference

29 August 2017

language of work or name

English

0 references

publication date

24 September 2013

1 reference

Breast Cancer Research and Treatment

29 August 2017

published in

1 reference

29 August 2017

volume

141

1 reference

29 August 2017

issue

3

1 reference

29 August 2017

page(s)

421-427

1 reference

CYP2D6 polymorphisms and the impact on tamoxifen therapy

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2700-1

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2700-1

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2700-1

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2700-1

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2700-1

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2700-1

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2700-1

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2700-1

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2700-1

Clinical and biomarker predictors of side effects from tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2700-1

Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2700-1

Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2700-1

CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2700-1

Polymorphism in the CYP2D6 Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: Data From the Italian Tamoxifen Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2700-1

10.1007/S10549-013-2700-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1052355153

0 references

1 reference